Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
IPCA Laboratories Ltd.
ClinicalTrials.gov Identifier:
NCT01603134
First received: May 18, 2012
Last updated: May 21, 2012
Last verified: May 2012
  Purpose

This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over comparative pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, human male subjects.


Condition Intervention Phase
Fasting State
Drug: Allopurinol
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Comparative Bioequivalence Study of Allopurinol 300 mg Tablets USP With Zyloprim® 300 mg in Normal, Healthy, Adult, Human Male Subjects Under Fasting Condition.

Resource links provided by NLM:


Further study details as provided by IPCA Laboratories Ltd.:

Primary Outcome Measures:
  • Bioequivalence is based on Cmax and AUC parameters. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Area Under Curve (AUC) and Cmax Sampling Hours: Pre-dose and at 00.25, 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.25, 02.50, 02.75, 03.00, 03.50, 04.00, 04.50, 05.00, 05.50, 06.00, 06.50, 07.00, 08.00, 10.00, 12.00, 16.00, 24.00, 48.00, 72.00 and 96.00 hours post-dose.


Enrollment: 32
Study Start Date: November 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allopurinol 300 mg Tablets USP
Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India
Drug: Allopurinol
300 mg tablet once a day
Other Name: Test Product
Active Comparator: Zyloprim®
Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA,
Drug: Allopurinol
300 mg tablet once a day
Other Name: Zyloprim®

Detailed Description:

Objective of this pivotal study was to assess the bioequivalence between Test Product: Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA, under fasting condition in normal, healthy, adult, human male subjects in a randomized crossover study.

The study was conducted with 32 healthy adult male subjects. In each study period, a single 300 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.

The duration of the clinical phase was 51 days including washout period of at 18 days between administrations of study drug in each study period.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male subjects in the range of 18 - 45 years of age (Inclusive).
  2. The healthy human male subjects, whose body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.
  3. Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).
  4. Subjects with normal findings, as determined by hematological tests, serum biochemistry, urine analysis, ECG and X-ray (if required).
  5. Willingness to follow the protocol requirements as evidenced by written informed consent.
  6. Agreeing to, not using any medication(either prescribed, OTC or alternate medicines), including vitamins and minerals for 14 days prior to study and during the course of the study.
  7. No history or presence of significant alcoholism in the past one year.
  8. Non-smokers, ex-smokers and light smokers will be included. "Light smokers are defined as someone smoking 10 cigarettes or less per day, ex-smokers as someone who completely stopped smoking for at least 3 months.

Exclusion Criteria:

  1. Requiring medication for any ailment including enzyme-modifying drugs in the previous 28 days, before day one (1) of dosing.
  2. Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
  3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases.
  4. Subjects with history of recent myocardial infraction, cardiac arrhythmias, cardiac failure and convulsions.
  5. Participation in a clinical drug study or bioequivalence study 90 days prior to present study.
  6. History of malignancy or other serious diseases.
  7. Refusal to abstain from food for at least ten (10.00) hours prior to administration of study drug and for at least four (04.00) hours post-dose.
  8. Refusal to abstain from water for at least one (01.00) hour prior to study drug administration of each study period and for at least two (02.00) hours post-dose except about 240 mL administered during administration dose.
  9. Any contraindication with blood sampling.
  10. Refusal to abstain from smoking or consumption of tobacco products 48.00 hours before dosing until the last sample collection of each period.
  11. Found positive in breath alcohol test done at the time of check-in for each study period.
  12. History of drug abuse in past one year.
  13. Use of xanthine-containing beverages or food, and fruit juice or grapefruit juice products for 48.00 hours prior to each drug dose.
  14. Blood donation 90 days prior to the commencement of the study.
  15. Subjects with positive HBsAg or Hepatitis-C, HIV tests and anti Treponema Palladium/Syphilis test.
  16. History of hypersensitivity to Allopurinol or any ingredients of formulation.
  17. History of problem in swallowing Tablet(s).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01603134

Locations
India
Accutest Research Lab (I) Pvt. Ltd.
Ahmedabad, Gujarat, India
Sponsors and Collaborators
IPCA Laboratories Ltd.
Investigators
Principal Investigator: Dr. Nirav Gandhi, M.D. Accutest Research Lab (I) Pvt. Ltd.
  More Information

No publications provided

Responsible Party: IPCA Laboratories Ltd.
ClinicalTrials.gov Identifier: NCT01603134     History of Changes
Other Study ID Numbers: Ipca/US/07/030
Study First Received: May 18, 2012
Last Updated: May 21, 2012
Health Authority: India: Ministry of Health
United States: Food and Drug Administration

Additional relevant MeSH terms:
Allopurinol
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Gout Suppressants
Antirheumatic Agents
Therapeutic Uses
Free Radical Scavengers
Antioxidants
Antimetabolites
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 14, 2014